Navigation Links
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Date:5/17/2013

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22nd at 11 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... Ind., July 27, 2017  Zimmer Biomet Holdings, Inc. ... quarter ended June 30, 2017.  The Company reported second ... 1.1% over the prior year period, and an increase ... 240 basis points of contribution from the LDR Holding ... the second quarter of 2016, or 0.3% on a ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 E.I. Medical Imaging (EIMI) ... Bimini SharkLab to custom design the worlds first ultrasound system to ... in their native habitat. In preparation for a piece produced ... Shark Week, Dr. Guttridge approached EIMI with the idea ... directly to hammerhead sharks underwater. ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... 27, 2017 , ... Somnoware, a leading provider of digital ... solution to its healthcare management platform. This solution provides physicians with remote scoring ... of scoring in the cloud is on par with doing it on a ...
(Date:7/27/2017)... (PRWEB) , ... July 27, 2017 , ... The Los Angeles leg of the US ... 2017 at 7:00pm and will be held at the Clive Davis Theater inside the Grammy ... Camo Jacket, chronicles the story of the iconic Welsh rock musician, Mike Peters (of The ...
(Date:7/27/2017)... ... July 27, 2017 , ... Team Novo Nordisk, the ... to the men’s pro squad as a stagiaire for the remainder of the 2017 ... debut on July 31st at the Tour of Utah. , “Every season we are ...
(Date:7/26/2017)... ... July 26, 2017 , ... Capillus, LLC has announced the redesign of ... new Flexible Fitting Design offers a more comfortable, adaptable fit and is available for ... improvements to the home-use laser therapy caps intended to improve both user experience and ...
(Date:7/26/2017)... ... ... A major challenge many labs face is a direct result from a ... dry cycle are a few common challenges that can overcome when following best practices. ... and advancements in laboratory freeze dryers that will improve quality and reduce the time ...
Breaking Medicine News(10 mins):